Cover Story
By Matthew Bin Han Ong
Tecentriq, Genentech's PD-L1 checkpoint inhibitor, is the first immunotherapy agent to report positive outcomes in breast cancer in a phase III trial—providing proof of principle that these drugs are active in treatment of triple-negative breast cancer.
In Brief
Clinical Roundup
Drugs & Targets
Trending Stories
- Undergrad intern at MSK poses a profound question: What if Henrietta Lacks had a Black doctor?
- Jeffrey Weber on his career, mentors: “Never ever ever ever blow your cool.”
- ODAC votes decisively in support of PD-L1 expression as predictive biomarker for checkpoint inhibitors
Vote may lead to rollback of some indications held by BMS and Merck - NCI-designated Basic Laboratory Cancer Centers get research done—efficiently
- Tom Lynch reflects on discovery of the EGFR mutations’ role in lung cancer
- Jeffrey S. Weber, pioneering immunologist and melanoma expert at NYU, dies at 72